• Market Capitalisation market-capitalisation-info $79 Mln
  • Price to Earnings Ratio price-to-earning 4.09
  • 12 Month Earnings monthly-earning $-15 Mln

Ocuphire Pharma Inc. (OCUP) Share Price

$2.71

As on 28-Nov-2023 16:00 EST

up-down-arrow $-0.08-2.87%

  • Prev Close info

    $2.79

  • Day's Openinfo

    $2.79

  • Today's Highinfo

    $2.79

  • Today's Lowinfo

    $2.63

  • Today's Volumeinfo

    252,542

  • 52 Week rangeinfo

    $2.48 - 6.60

Please wait...

Ocuphire Pharma Inc. (OCUP) Stock Performance

YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Ocuphire Pharma (OCUP)
-23.23 -1.81 -32.08 -12.83 -25.60 -45.08 -34.63
S&P BSE Sensex*
9.96 4.89 2.93 7.03 14.86 13.37 12.54
S&P Small-Cap 600#
-5.82 -5.34 -13.90 -6.30 5.30 2.98 5.53
As on 28-Nov-2023  |  *As on 29-Nov-2023  |  #As on 26-Oct-2023
2022
2021
2020
2019
2018
2017
2016
Ocuphire Pharma (OCUP)
-5.36 -42.53 -15.05 -82.89 -53.77 42.35 -60.91
S&P Small-Cap 600
-17.42 25.27 9.57 20.86 -9.70 11.73 24.74
S&P BSE Sensex
4.44 21.99 15.75 14.38 5.87 27.91 1.95

Valuation

Stock
Peer Median
Please wait...

Growth & Efficiency

Stock
Peer Median
Please wait...

Solvency

Is there a threat to this company's solvency in the future?

Financial Manipulation

Can creative accounting be detected through the financial numbers?

Ocuphire Pharma Inc. (OCUP) Peer Comparison

search
search
search
search
    Please wait...

    Valuation Chart of Ocuphire Pharma Inc. (OCUP)

      Please wait...
        Please wait...

        Financials

        Please wait...
        Please wait...
        Please wait...

        Shareholding Pattern

        Other details of Ocuphire Pharma Inc. (OCUP)

        Founder, CEO, Pres, Treasurer & Vice Chair of the Board

        Ms. Mina Patel Sooch M.B.A., MBA

        VP of Fin. & Principal Accounting Officer

        Ms. Amy Zaremba Rabourn C.P.A., CPA, MAcc

        Headquarters

        Farmington Hills, MI

        FAQs for Ocuphire Pharma Inc. (OCUP)

        The total asset value of Ocuphire Pharma Inc. (OCUP) stood at $ 50 Mln as on 31-Mar-23

        The share price of Ocuphire Pharma Inc. (OCUP) is $2.71 (NASDAQ) as of 28-Nov-2023 16:00 EST. Ocuphire Pharma Inc. (OCUP) has given a return of -25.6% in the last 3 years.

        Ocuphire Pharma Inc. (OCUP) has a market capitalisation of $ 79 Mln as on 09-Jun-2023. As per Value Research classification, it is a Small Cap company.

        The P/B ratio of Ocuphire Pharma Inc. (OCUP) is 5.40 times as on 09-Jun-2023, a 1.13% premium to its peers’ median range of 2.54 times.

        The P/E (price to earnings) ratio of Ocuphire Pharma Inc. (OCUP) is 4.09 times as on 09-Jun-2023.

        Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
        Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
        Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
        Step 4. Search for the Ocuphire Pharma Inc. (OCUP) and enter the required number of quantities and click on buy to purchase the shares of Ocuphire Pharma Inc. (OCUP).

        Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate for dim light or night vision disturbances; and for pharmacologically induced mydriasis and presbyopia. The company also develops APX3330, a twice-a-day oral tablet to target pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema; and APX2009 and APX2014 second generation preclinical product candidates and analogs of APX3330. The company is headquartered in Farmington Hills, Michigan.

        The CEO & director of Ms. Mina Patel Sooch M.B.A., MBA. is Ocuphire Pharma Inc. (OCUP), and CFO & Sr. VP is Ms. Amy Zaremba Rabourn C.P.A., CPA, MAcc.

        The promoters of Ocuphire Pharma Inc. (OCUP) have pledged 0% of the total equity as on Mar-23.

        Ocuphire Pharma Inc. (OCUP) Ratios
        Return on equity(%)
        71.71
        Return on capital employed(%)
        --
        Debt-to-equity ratio
        0
        Dividend yield(%)
        0

        No, TTM profit after tax of Ocuphire Pharma Inc. (OCUP) was $-15 Mln.

        Edit peer-selector-edit
        Please wait...
        Please wait...

        Key Facts

        • Market cap market-cap-information $78.78 Mln
        • Revenue (TTM)revenue-information $41.60 Mln
        • Earnings (TTM) earning-information $-15.25 Mln
        • Cash date-information $39.01 Mln
        • Total Debt info $0.00 Mln
        • Insider's Holding 5.21%
        • Liquidity liquidity High
        • 52 Week range week-range $2.48 - 6.60
        • Shares outstanding share-outstanding 20,952,200
        • 5 Years Aggregate:

          CFO: $-16.21 Mln

          EBITDA: $-18.36 Mln

          Net Profit: $-112.40 Mln

        About The Company

        • IPO Date 23-May-2005
        • Founder, CEO, Pres, Treasurer & Vice Chair of the Board Ms. Mina Patel Sooch M.B.A., MBA
        • VP of Fin. & Principal Accounting Officer Ms. Amy Zaremba Rabourn C.P.A., CPA, MAcc
        • Listing key-listing NASDAQ: OCUP
        • Country United States
        • Headquarters headquarters Farmington Hills, MI
        • Website website https://www.ocuphire.com
        • Business

          Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily...  preservative-free eye drop formulation of phentolamine mesylate for dim light or night vision disturbances; and for pharmacologically induced mydriasis and presbyopia. The company also develops APX3330, a twice-a-day oral tablet to target pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema; and APX2009 and APX2014 second generation preclinical product candidates and analogs of APX3330. The company is headquartered in Farmington Hills, Michigan.  Read more

        Demystifying Stocks.

        At Value Research, we believe it's best to understand investments before diving in. And since 1990, we've been doing exactly that – helping & guiding lakhs of Indians with their investing journey. Join the journey.

        Sign Up for Free
        demystifying-mutual-fund

        What can Value Research do for you?

        solidify-your-fundamentals
        Solidify your fundamentals

        Learn the principles, mindset and tools you need to become a successful Mutual Fund and Stock investor from the masters who have been doing this for decades.

        track-all-your-investments
        Track all your investments

        Use India's most advanced investment tracker to track, analyse and get updates and insights on your investments.

        get-guidance-from-our-experts
        Get guidance from our experts

        Get an analysis of your portfolio along with actionable, general tips and insights, guidance on where to invest based on your goals, and experts' opinions on individual Mutual Funds and Stocks.

        get-access-to-exclusive-analytics
        Get access to exclusive analytics

        Value Research offers the most advanced and detailed data & analytics available on Mutual Funds and Stocks. Sign up and unlock the power yourself.

        Explore it yourself, for free

        Sign up and get access to:

        Unlimited access to advice from India's top experts

        The most comprehensive analysis of funds and stocks in India

        A holistic portfolio manager to help track all your investments easily

        And much more, like guides, tools, webinars, videos and eBooks.

        share-fund-plan-icon